Interferon-mediated cytokine induction determines sustained virus control in chronic hepatitis C Virus Infection

Journal of Infectious Diseases

Volumn 212, Issue 11, 2015, Pages 746-754

  Wandrer, Franziska ^a   Falk, Christine S ^b   John, Katharina ^a   Skawran, Britta ^a   Manns, Michael P ^a   Schulze Osthoff, Klaus ^c,d   Bantel, Heike ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Institute of Transplant Immunology   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Cytokines; HCV; IFN ; TRAIL

Indexed keywords

ALPHA INTERFERON; CYTOKINE; I KAPPA B KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; PEGINTERFERON ALPHA; RIBAVIRIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS RNA;

ADULT; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HELPER CELL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; LIVER; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PHYSIOLOGY; TREATMENT FAILURE; VIROLOGY; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG TREATMENT FAILURE; HUMAN CELL; HUMAN TISSUE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TH2 CELL; UPREGULATION; VIRAL CLEARANCE;

ADULT; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; I-KAPPA B KINASE; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LIVER; MALE; MAP KINASE KINASE 4; MIDDLE AGED; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, HELPER-INDUCER; TREATMENT FAILURE;

EID: 84958652626     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv505     Document Type: Article

References (50)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-42
2. Lin MV, King LY, Chung RT. Hepatitis C virus-associated cancer. Annu Rev Pathol 2015; 10:345-70
3. Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ 2003; 10:S48-58
4. Bantel H, Lügering A, Poremba C, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001; 34:758-67
5. Bantel H, Lügering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40:1078-87
6. Volkmann X, Cornberg M,Wedemeyer H, et al. Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 2006; 43:1311-6
7. Yoon JH, Gores GJ. Death receptor-mediated apoptosis and the liver. J Hepatol 2002; 37:400-10
8. Hiramatsu N, Hayashi N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19:1354-9
9. Mita E, Hayashi N, Iio S, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204:468-74
10. Sedger LM, Shows DM, Blanton RA, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163:920-6
11. Sträter J, Walczak H, Pukrop T, et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology 2002; 122:659-66
12. Volkmann X, Fischer U, Bahr MJ, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007; 46:1498-508
13. Brost S, Zimmermann A, Koschny R, et al. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathol Res Pract 2014; 210:83-91
14. Jang JY, Kim SJ, Cho EK, et al. TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications. PLoS One 2014; 9:e98171
15. Mundt B, Kühnel F, Zender L, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003; 17:94-6
16. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189:1451-60
17. Stegmann KA, Bjrkstrm NK, Veber H, et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010; 138:1885-97
18. Pak-Wittel MA, Yang L, Sojka DK, Rivenbark JG, Yokoyama WM. Interferon-γ mediates chemokine-dependent recruitment of natural killer cells during viral infection. Proc Natl Acad Sci USA 2013; 110:E50-9
19. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014; 14:36-49
20. Makowska Z, Heim MH. Interferon signaling in the liver during hepatitis C virus infection. Cytokine 2012; 59:460-6
21. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002; 99:15669-74
22. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-9
23. Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124:3352-63
24. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002; 99:15661-8
25. Kokordelis P, Krämer B, Krner C, et al. An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency viruspositive patients. Hepatology 2014; 59:814-7
26. Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2012; 55:39-48
27. Shigeno M, Nakao K, Ichikawa T, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 2003; 22:1653-62
28. Liedtke C, Grger N, Manns MP, Trautwein C. Interferon-alpha enhances TRAILmediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells. J Hepatol 2006; 44:342-9
29. Ahlenstiel G, Titerence RH, Koh C, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010; 138:325-35
30. Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141:1231-9
31. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol 2014; 61:S14-25
32. Sarhan D, D'Arcy P, Wennerberg E, et al. Activated monocytes augment TRAILmediated cytotoxicity by human NK cells through release of IFN-γ. Eur J Immunol 2013; 43:249-57
33. Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction. Gut 2011; 60:268-78
34. Fulda S, Debatin KM. IFNgamma sensitizes for apoptosis by upregulating caspase- 8 expression through the Stat1 pathway. Oncogene 2002; 21:2295-308
35. Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74:360-9
36. Diago M, Castellano G, García-Samaniego J, et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55:374-9
37. Lagging M, Romero AI,Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44:1617-25
38. Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140:1021-31
39. Lee IC, Huang YH, Su CW, et al. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study. PLoS One 2013; 8:e76798
40. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:1006-7
41. Miyagi T, Takehara T, Nishio K, et al. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. Hepatology 2010; 53:424-30
42. Dill MT, Makowska Z, Duong FH, et al. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 2012; 143:777-86
43. Dill MT, Makowska Z, Trincucci G, et al. Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest 2014; 124: 1568-81
44. Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR. Double-stranded RNAdependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci USA 1994; 91:6288-92
45. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol 2011; 12:695-708
46. Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001; 3:409-16
47. Jennewein C, Karl S, Baumann B, Micheau O, Debatin KM, Fulda S. Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95- mediated apoptosis of glioblastoma cells. Oncogene 2012; 31:1468-74
48. Pfeffer LM, Kim JG, Pfeffer SR, et al. Role of nuclear factor-kappaB in the antiviral action of interferon and interferon-regulated gene expression. J Biol Chem 2004; 279:31304-11
49. Yanase N, Hata K, Shimo K, Hayashida M, Evers BM, Mizuguchi J. Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res 2005; 310:10-21
50. Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biol Ther 2012; 13:1143-51